| Name | Title | Contact Details |
|---|---|---|
Devon Sharp |
Associate General Counsel | Profile |
Grant Riedesel |
Head of Legal, Corporate Development | Profile |
Tim Stow |
Global Head of Ethics and Compliance | Profile |
Sean Griffin |
Vice President of Regulatory Affairs | Profile |
Easter Seals Waterbury, Connecticut is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Harvard Vanguard Medical Associates, our staff is our most important resource. That's why we offer challenging work, career advancement, competitive salaries and a benefits program that is among the best in the marketplace. The following summary is
Preferred Health Strategies is a Rye, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Agility Healthcare Solutions is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.